Please try another search
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.
Name | Age | Since | Title |
---|---|---|---|
Antonio Lanzavecchia | - | - | Scientific Advisor |
Lindsey Rolfe | 56 | 2024 | Independent Director |
Kathleen D. LaPorte | 62 | 2024 | Independent Director |
Brian G. Atwood | 71 | 2024 | President, CEO & Chairman |
Daniel Mark Corey | 45 | 2016 | Founder, CTO & Director |
Robyn Rapaport | 31 | 2024 | Independent Director |
Christopher B. Ehrlich | 54 | 2021 | Independent Vice Chairman |
Adrian Bot | - | - | Scientific Advisor |
Michael Byrnes | 47 | 2024 | Independent Director |
Lawrence Corey | 77 | - | Head of Scientific Advisory Board |
Rafi Ahmed | - | - | Scientific Advisor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review